Drug Trial Radar · NCT06311656
A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Mar 19, 2024
Primary completion
Oct 4, 2024
Study completion Oct 4, 2024
Sponsor
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.
Conditions
- Healthy
Interventions
LY4100511 (DC-853)Drug
Administered orally fasted
LY4100511 (DC-853)Drug
Administered orally fasted.
LY4100511 (DC-853)Drug
Administered orally fed and fasted.
LY4100511 (DC-853)Drug
Administered orally fed and fasted.
PlaceboDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)Time frame: Baseline up to 47 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Los Angeles, Inc
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.